Study #2024-1323
A phase 1b/2, open-label, master protocol study of BTK-degrader BGB-16673 in combination with other agents in patients with relapsed or refractory B-cell malignancies
MD Anderson Study Status
Enrolling
Treatment Agent
Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab
Description
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Study phase:
Physician name:
Nitin Jain
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.